Loading...

Office Address

123/A, Miranda City Likaoli
Prikano, Dope

Phone Number

+0989 7876 9865 9

+(090) 8765 86543 85

Email Address

info@example.com

example.mail@hum.com

Neo Kumfurt

Neo Kumfurt Robocard 5/10mg (Pimobendan & Benazepril) Tablet for Dogs (pack of 30 tablets)

(0 Reviews)
SKU: PRD591
Prefer to which animal: Dog
โ‚น1,833.00

Inclusive of all taxes

COD Available
Product Details
Product type Oral Tablets
Volume / Quantity Pack of 30 Tablets (Box/Container)
Target Species Canines Only (Dogs diagnosed with chronic cardiac disorders or insufficiency)
Common Use Case Medical management of congestive heart failure (CHF) secondary to Dilated Cardiomyopathy (DCM), Myxomatous Mitral Valve Disease (MMVD), or atrioventricular valve insufficiency.

Neo Kumfurt Robocard 5/10mg is a prescription-only, dual-action veterinary cardiovascular medication designed to manage congestive heart failure (CHF) in medium and large breed dogs. It features a clinically proven, fixed-dose combination of two active cardiac compounds: Pimobendan (5mg) and Benazepril Hydrochloride (10mg).

Pimobendan acts as a positive inotrope and vasodilator (inodilator) that strengthens the force of heart muscle contractions and widens blood vessels to boost systemic circulation. Concurrently, Benazepril operates as a potent Angiotensin-Converting Enzyme (ACE) inhibitor, relaxing constricted pathways to lower arterial blood pressure and ease peripheral resistance. Together, this comprehensive approach minimizes the heart's workload, prevents fluid backup (edema), and provides essential relief from clinical symptoms like chronic coughing and lethargy. Administered orally on an empty stomach at strict 12-hour intervals, these palatable chewable tablets noticeably enhance physical stamina and improve long-term survival under veterinary supervision.

Neo Kumfurt Robocard 5/10mg Tablets are manufactured and marketed by Neo Kumfurt Solutions (a division of Kaizen Remedies Pvt. Ltd.), an innovative animal healthcare company headquartered in India, recognized for producing globally benchmarked and highly efficacious companion animal therapeutics.